Maternal regulation of early life origin b cells

Active Project Grant Awarded Last action

Award ID
F31AI200407
Recipient
Awarding agency
Obligated
$95,636

Award facts

Assistance listing
93.855 Allergy and Infectious Diseases Research
Completion date 0% complete
Originally
Place of performance
Seattle, WA 98109, USA

Award details come from USAspending.gov.

Description

As the agency reported it.

Abstract
In early life, the immune system rapidly develops in close interaction with the intestinal microbiome, a process influenced by breastmilk. Breastmilk contains immunomodulatory factors, including maternal antibodies (matabs), that support immune-microbiome homeostasis and reduce the risk of mucosal, immune-mediated, and metabolic disorders later in life, compared to formula FED counterparts. Among these bioactive factors, matabs play an essential role in shaping microbiota composition, controlling microbial colonization, modulating gene expression, and directing early immune development. However, how the absence of matabs alters these interactions and influences long-term immunity remains unclear. This project aims to define how maternal antibodies regulate neonatal adaptive immune-microbiota interactions and shape durable mucosal b cell immunity. Previous work in mice has shown that neonates lacking matabs exhibit increased mucosal, microbiota- dependent TFH and associated germinal center (GC) b cell responses during the weaning transition. Proper regulation of mucosal TFH cells and t-dependent (TD) antibody production is essential for maintaining GUT homeostasis. Disruptions in early-life immune-microbiota interactions are increasingly linked to later development of immune-mediated diseases. Genetic fate-mapping approaches have revealed that GC b cells activated during the weaning period give rise to antibody-secreting cells that persist in the adult lamina propria, suggesting durable immunological imprinting during this critical window. Two specific aims will be pursued: (1) to identify the immune-activating microbes that drive dysregulated adaptive immune responses in the absence of matabs, and (2) to characterize the long-lived neonatal mucosal b cell response derived from early-life GC b cells. The project will employ cutting edge fate mapping tools, innovative transgenic mouse models, antibiotic depletion, 16S rrna sequencing, microbiota flow cytometry, and single-cell transcriptomics approaches to map these responses. Elucidating how breastfeeding shapes neonatal immune-microbiota interactions and long-term mucosal immunity could benefit individuals who are not exclusively breastfed for the six-months of age as recommended- a population estimated to be approximately two-thirds of all infants in the world. Ultimately, these insights may inform the development of targeted intervention- such as passive immunization, vaccines, or enriched formulas- to promote immune balance in non-breastfed infants, thereby reducing the long-term burden of allergic, inflammatory, mucosal, and metabolic diseases rooted in early-life immune dysfunction.

Transactions

Action Obligated Date
Amendment $47,818
Amendment $47,818
Original award $0

Quick answers

Who received award F31AI200407?

F31AI200407 was awarded to Fred Hutchinson Cancer Center by National Institute of Allergy and Infectious Diseases (National Institutes of Health) on November 23, 2026.

How much is award F31AI200407 worth?

$95,636 has been obligated on F31AI200407.

On GovTribe

See this award's full record

  • Every transaction and subaward
  • The recipient's other awards and teaming partners
  • Similar grant awards
  • Ask GovTribe AI about this award
Try for free Login